

Alberta Immunization Program History

Updated: May 2024

This document contains up-to-date biological product start and end dates, and includes historical program notes up to August 24, 2016. For program notes after this date, please refer to the [Table of AIP updates](#).

'Start Date' refers to the date when a product began being offered as a provincially funded product through the Alberta immunization program.

'End Date' refers to the date when a product is no longer offered as a provincially funded product through the Alberta immunization program.

Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
BCG	BCG	Bacillus Calmette-Guérin (TB): BCG Vaccine (freeze-dried)	Connaught	1956-01-01	2007-08-09
				1956-01-01	2018-06-30 (FNIHB)
Botulism	BA	Botulism Antitoxin	Multiple manufacturers	1962-06-12	
		Botulism Antitoxin: Bivalent A & B Botulism Antitoxin: Type E	Connaught/ Sanofi Pasteur	unknown	2011-10-26
		Botulism Antitoxin – Behring (Equine) Types A, B, & E	Novartis	2011-10-27	
	BA-7	Botulism Antitoxin Heptavalent (Equine) Types A, B, C, D, E, F, & G	Emergent BioSolutions (Canada Inc.)	2016-12	
	BAIG	Botulism Immune Globulin Intravenous (Human) - BabyBIG®	California Department of Public Health	2013-05-27	2022-10-26
COVID-19	COVPBmRNA	COVID-19 BNT 162b2 – mRNA (Comirnaty)	Pfizer-BioNTech	2020-12-16	2023-07-31
	COVMODmRNA	COVID-19 mRNA 1273 - mRNA (SpikeVax)	Moderna	2020-12-28	2023-04-20
	COVAUVec	AZ-COVID-19 ChAdOx1 - NR viral Vector (Vaxzevria)	AstraZeneca	2021-03-10	2022-04-30
	COVSIIVec	COVISHIELD SII - COVID-19 ChAdOx1 - NR viral Vector	Verity Pharmaceuticals Inc & Serum Institute of India (In partnership with AZ)	2021-03-10	2022-04-30

Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
	COVJANVec	COVID-19 Ad26 SARS - NR viral Vector	Janssen/Johnson & Johnson	2021-11-12	June 30, 2023
	COVPB5y-11ymRNA	PEDIATRIC COVID19 BNT162b2-mRNA 5 yrs to 11 yrs (Cominarty)	Pfizer-BioNTech	2021-11-26	2023-08-01
	COVMODmRNA	PEDS 6-11 yrs COVID-19 mRNA 1273 – mRNA (Moderna/SpikeVax)	Moderna	2022-04-12	2023-04-20
	COVNVASub	Recombinant spike protein, unspecified (Nuvaxovid)	Novavax	2022-04-12	June 30, 2023
	COVMOD6m-5ymRNA	PEDS 6mos-5yrs COVID-19 mRNA 1273 – mRNA (Moderna/SpikeVax)	Moderna	2022-08-02	2023-08-01
	COVMODmRNABA1	COVID-19 Moderna (Spikevax) Bivalent Vaccine-BA1	Moderna	2022-09-21	2023-04-15
	COVPBmRNABA45	COVID-19 Pfizer-BioNTech (Comirnaty) Bivalent Vaccine-BA4/5	Pfizer-BioNTech	2022-10-24	2023-10-02
	COVPB6m-4ymRNA	PEDS 6mos-4 yrs COVID19 BNT162b2 - mRNA (Pfizer/Cominarty)	Pfizer-BioNTech	2022-11-14	2023-08-01
	COVPB5-11mRNA45	COVID-19 Pfizer-Bivalent Vaccine-BA.4/5 (5 yrs to 11 yrs)	Pfizer-BioNTech	2023-01-05	2023-10-02
	COVMODmRNABA45	COVID-19 Moderna (Spikevax) Bivalent Vaccine-BA.4/5	Moderna	2023-08-02	2023-10-02
	COVMODmRNAXBB	COVID-19 Moderna (Spikevax) XBB.1.5 (6 months of age and older)	Moderna	2023-10-02	
	COVPBmRNAXBB	COVID-19 Pfizer-BioNTech XBB.1.5 (5 to 11 years of age)	Pfizer-BioNTech	2023-10-16	
	COVPBmRNAXBB	COVID-19 Pfizer-BioNTech XBB.1.5 (12 years of age and older)	Pfizer-BioNTech	2023-10-16	
	COVNVASubXBB	COVID-19 Novavax Nuvaxovid XBB.1.5 (12 years of age and older)	Novavax	2024-01-05	
Diphtheria	DA	Diphtheria Antitoxin	Multiple manufacturers	1895-01-01	
		Diphtheria Antitoxin: Anti Diphtheria Serum	Instituto Butantan, Brazil	2006-03-08	2010-10-31
		Diphtheria Antitoxin (equine)	Institute of Immunology Inc, Croatia	2023-04-25	
				2011-04-21	2014-03-31

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 2 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
		Diphtheria Antitoxin (equine)	VINS Bioproducts Limited, India	2014-06-11	
	DRT	Diphtheria Reaction Test		1923-01-01	1996-01-01
	D	Diphtheria Toxoid		1930	1994-08-01
	D	Diphtheria Toxoid (fluid)		1954-04-01	1994-08-01
	DD	Diphtheria Toxoid (fluid-diluted)		1954-04-01	1994-08-01
Diphtheria and Pertussis	No code	Diphtheria Toxoid and Pertussis Combined		1943	1948-01-01
Diphtheria and Tetanus	DT	Diphtheria/Tetanus Toxoids (pediatric)		1948-01-01	1998-12-31
DT-IPV		Diphtheria/Tetanus/IPV (pediatric)	Connaught	1996-07-01	2005-10-01
DTaP		Diphtheria/Tetanus/Acellular Pertussis: Tripacel®	Connaught/Aventis Pasteur	1997-07-01	1999-01-01
Tdap	Tdap	Diphtheria/Tetanus/Acellular Pertussis	Sanofi Pasteur Adacel®	2004-09-01	
			GlaxoSmithKline Boostrix®	2008-11-30	
		<p>2004-09-01 - Diphtheria/Tetanus/Acellular Pertussis (dTdap) replaced Td as routine Grade 9 booster.</p> <p>2009-02-02 - One lifetime dose of dtap vaccine recommended for individuals 65 years of age and older when presenting for Td booster.</p> <p>2012-01-01 - dtap one-time adult booster dose replacing Td (not needed if dtap at age 12 years or older).</p> <p>2012-02-01 - dtap was implemented for the following adult populations:</p> <ul style="list-style-type: none"> - HCWs providing care to children under 12 months of age. - Adults who have not received an adolescent or adult dose of dtap vaccine. <p>2014-03-02 - dtap one-time adult booster dose replacing Td if have not already received a dose of dtap in adulthood.</p>			
DPT	DPT	Diphtheria/Whole Cell Pertussis/Tetanus		1948-01-01	1997-06-30
DPTP	DPTP	Diphtheria/Whole Cell Pertussis/Tetanus/IPV: Quadracel®	Connaught	1994-08-02	1997-06-30
DTaP-IPV	DTaP-IPV	Diphtheria/Tetanus/Acellular Pertussis/IPV: Quadracel®	Connaught/Sanofi Pasteur	1997-07-01	2017-07
		Diphtheria/Tetanus/Acellular Pertussis/IPV: Infanrix®-IPV	GlaxoSmithKline	2012-11-20	2017-07
		<p>1997-07 - Quadracel® containing the acellular pertussis component became available in the routine immunization program.</p> <p>2012-09-11 - dtap-IPV routine booster for 4 – 6 year olds replacing DTaP-IPV.</p> <p>2012-11-20 - Infanrix®-IPV became available for primary immunization in children with delayed immunization schedules.</p>			
Tdap-IPV	Tdap-IPV	Diphtheria/Tetanus/Acellular Pertussis/IPV: Boostrix®-IPV	GlaxoSmithKline	2012-10-11	

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 3 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)	
		2012-09-11 - dTap-IPV routine booster for 4 – 6 year olds replacing DTaP-IPV.				
DPTPHib	DPTPHib	Diphtheria/Whole Cell Pertussis/Tetanus/IPV/Hib: Penta	Connaught	1994-08-02	1997-06-30	
DTaP-IPV-Hib	DTaP-IPV-Hib	Diphtheria/Tetanus/Acellular Pertussis/IPV/Hib: Pentacel®	Connaught/Sanofi Pasteur	1997-07-01	2007-11-30	
		Diphtheria/Tetanus/Acellular Pertussis/IPV/Hib: Pediacel®	Sanofi Pasteur	2007-11-30		
		Diphtheria/Tetanus/Acellular Pertussis/IPV/Hib: Infanrix®-IPV/Hib	GlaxoSmithKline	2012-11-20		
DTaP-IPV-HIB-HB	DTaP-IPV-HIB-HB	Diphtheria/Tetanus/Acellular Pertussis/IPV/Hib/Hepatitis B: Infanrix hexa®	GlaxoSmithKline	2016-06-01		
		2016-04-26 - Indicated for children under 2 years of age eligible for DTaP-IPV-Hib and Hepatitis B. 2016-06-01 – Introduced for children under 24 months of age for infants born to infected mothers/caregivers, household contacts of hepatitis B carriers, and infants whose families come from endemic countries. 2018-03-01 – Universal infant program introduced.				
DPT-IPV-Killed Measles Quint	No code	Diphtheria/Whole Cell Pertussis/Tetanus/IPV/Killed Measles: Quint		1968-01	1970-07	
Ebola Vaccine		Ebola Zaire Virus	Merck Canada	2022-11-09		
HIB	No code	<i>Haemophilus influenzae</i> type b: b-CAPSA	Mead Johnson	1987-08-01	1987-10-01	
	PRP	<i>Haemophilus influenzae</i> type b (PRP)	Connaught	1987-10-01	1988-03-01	
	PRPD	<i>Haemophilus influenzae</i> type b	Connaught	1988-03-16	1992-05-18	
	OMP	<i>Haemophilus influenzae</i> type b	Merck Frosst	1990-01-01	1994-08-02	
	HbOC	<i>Haemophilus influenzae</i> type b	Lederle-Praxis	1992-05-19	1993-02-01	
	PRPT		<i>Haemophilus influenzae</i> type b	Connaught/Sanofi Pasteur	1993-02-01	
			<i>Haemophilus influenzae</i> type b: Hiberix®	GlaxoSmithKline	2013-01-22	
	1987-07 - <i>Haemophilus influenzae</i> type b (PRP) for 2 to 3 year olds (single antigen). 1988 - <i>Haemophilus influenzae</i> type b (PRPD) for 18 months olds. 1994-08 - <i>Haemophilus influenzae</i> type b (PRPT) introduced into routine immunization schedule for 2 month olds in diphtheria, tetanus, pertussis, polio and Hib combination vaccine. 2015-02 - Act-Hib®/Hiberix® indicated for individuals 5 years and older regardless of previous Hib immunization with specified chronic conditions.					
Hepatitis A	HAV	Hepatitis A – adult: Havrix® 1440 and Vaqta®	GlaxoSmithKline Merck Frosst	1994-01-01		

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 4 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
		Hepatitis A pediatric: Havrix® 720 and Vaqta®.	GlaxoSmithKline Merck Frost	1997-06-01	
		Hepatitis A – Avaxim® Pediatric (outbreak in Edmonton)	Sanofi Pasteur Ltd.	2013-02	
		1994-01-01 - Introduced into program for eligible (at risk) adults. 1997-06 - Introduced into program for eligible (at risk) children. 2016-06-30 - Hepatitis A vaccines – Havrix® and Vaqta®. Updated indications to include infants 6 months and older eligible for hepatitis A vaccine.			
Hepatitis A and B	HABV	Hepatitis A and B combined: Twinrix®	GlaxoSmithKline	1997-01-01	
		2014-01-10 - Hepatitis A and hepatitis B combined vaccine (Twinrix®) introduced for adults requiring both hepatitis A and B vaccines.			
Hepatitis B	HBV	Hepatitis B: Recombivax HB® (neonatal program – infants at high risk)	Merck Frosst	1983-01-01	
		Hepatitis B: Recombivax HB® (3 mL multi-dose vials with thimerosal) (Grade 5)	Merck Canada	1995-09	2010-10-31
		Hepatitis B: Engerix® B Adult for individuals allergic to thimerosal	GlaxoSmithKline	2002	
		Hepatitis B: Engerix® B Pediatric	GlaxoSmithKline	2011	
	HBTmf	Hepatitis B: Recombivax HB® - Thimerosal free (infants younger than age one)	Merck Frosst	2002-05-01	2011-05-01
		1983-01 - Hepatitis B vaccine for high-risk infants younger than one year of age. Hepatitis B dialysis strength (Recombivax®) introduced. 1995-09 - Hepatitis B Vaccine routine school program for Grade 5 students (3-dose schedule). 1999-09 - Hepatitis B catch-up for Grade 12 students (end date 2002-06). 2011-08 - Recombivax HB® change in dosage for all individuals 0 – 10 years of age from 0.25 mL to 0.5 mL including students in Grade 5. 2015-01-02 - Hepatitis B indications to include individuals with congenital immunodeficiencies, individuals infected with HIV and susceptible adults who have immigrated to Canada from areas where there is a high prevalence of hepatitis B.			
HBVD		Hepatitis B for Dialysis	Merck Frosst	1983-01-01	
Hepatitis B Immune Globulin	HBIG	Hepatitis B Immune Globulin	Multiple manufacturers – accessed through Canadian Blood Services	1971-01-01	
Herpes Zoster – Shingrix Vaccine		Herpes Zoster – Shingrix Vaccine – 18+ SOT recipients	GSK	2021-09-01	
HPV	HPV	Human Papillomavirus Quadrivalent: Gardasil® (Grade 5)	Merck Canada	2008-09-01 (girls) 2014-09-01 (boys)	2015-08-31

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 5 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
		(Grade 9 catch up 2009-09)			
	HPV9	Human Papillomavirus Quadrivalent: Gardasil® 9	Merck Canada	2016-09-01	
		2009-09-01 - Human Papillomavirus types 6, 11, 16 & 18 vaccine (Gardasil®) four year catch-up for Grade 9 females (end date: 2013-06-30). 2012-11 – Eligibility expanded to include: <ul style="list-style-type: none"> - Females who were eligible in grade 5 would remain eligible to the end of Grade 12. - Male and female recipients of HSCT 9 years up to and including 17 years of age. 2014-07 – HPV eligibility expanded to include male recipients of HSCT 9 years up to the end of Grade 12. 2014-09-01 - Human Papillomavirus vaccine (Gardasil®) four year catch-up for Grade 9 males.(end date: 2018-06-30). 2014-09-01 - Human Papillomavirus Vaccine (Gardasil®) to include all students (females and males) in Grade 5.			
Immune Globulin	IG	Immune Serum Globulin (human)	Multiple manufacturers	1987-02-18	
Influenza	FLU	Influenza whole cell: Fluviral® & Vaxigrip®	GlaxoSmithKline Sanofi Pasteur	1943-01-01	1992 approx.
		Influenza split virus vaccine: Fluviral® & Vaxigrip® (first used in Canada in approximately 1992)	Biochem/ GlaxoSmithKline Connaught/ Sanofi Pasteur	1992 approx.	
	H1N1-09-AD	Influenza H1N1 Pandemic adjuvanted: Arepanrix™ H1N1 – universal immunization	GlaxoSmithKline	2009-10-19	2010-10-31
	H1N1-09	Influenza H1N1 Pandemic without adjuvant - pregnant women	CSL Australia	2009-11	2009-11
		Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant) – pregnant women and individuals 10 to 64 years without immune compromising conditions and who specifically request vaccine without adjuvant	GlaxoSmithKline	2009-12-01	2010-08
	FLU	Influenza Trivalent: Agriflu®	Novartis	2011-10	
		Influenza Live attenuated trivalent: Flumist® – Pilot/Research 2011 -2012 influenza season included 2000 doses	AstraZeneca	2011-10	2012-03
		Influenza Live attenuated trivalent: Flumist® -	AstraZeneca	2012-10	2014-15

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 6 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
		Vaccine of choice for children 2 – 17 years of age			
		Influenza Trivalent: Fludac®	Novartis	2014-09	
		Influenza Trivalent Influvac®	BGP Pharma ULC	2015-10	
		Influenza Live attenuated: Flumist® Quadrivalent	AstraZeneca	2014-10	2016-04
		Influenza Live attenuated quadrivalent vaccine: Flumist® Quadrivalent - Vaccine of choice for children 2 – 17 years of age	AstraZeneca	2014-10	2017-04
		Influenza Inactivated Quadrivalent: Fluzone®	Sanofi Pasteur Inc	2015-10	
		Influenza Inactivated Quadrivalent: Flulaval® Tetra	GlaxoSmithKline Inc	2018-10	
		<p>1992 (approx.) - Influenza vaccine split virus Influenza split virus vaccine first used in Canada in approximately 1992. (Fluviral® & Vaxigrip®)</p> <p>2008-10 - Influenza vaccine recommended for healthy children 24 – 59 months of age and healthy adults 50 – 64 years of age.</p> <p>2009-10 - Influenza vaccine for H1N1 Pandemic universal program for everyone six months of age and older.</p> <p>2009-10 - Influenza seasonal vaccine universal program to include all Albertans six months of age and older.</p> <p>2009-12-01 - Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (without adjuvant) for pregnant women and individuals 10 to 64 years without immune compromising conditions specifically requesting vaccine without adjuvant.</p> <p>2014-10 - Fludac® for Albertans 65 years of age and older living in continuing care facilities such as long term care or supportive living accommodations (such as Daily Assisted Living (DAL), Seniors Lodges, AHS Home Care Program) and those living in congregate living settings who share common eating areas.</p> <p>2015-08-12 - Influenza Vaccines 2015-2016 season: Fludac® (all Albertans aged 65 years and older.), Flumist® Quadrivalent, Fluviral, Influvac®. (This is the vaccine of choice for adults 18 to 64 years of age).</p>			
Measles	KMEA	Killed Red Measles		1966	1970-07
	EZM	E/Z Measles (Live)	(Edmonston-Zagreb, Live)	1969-01-01	1971-01-01
	MEA	Measles (Red) dose measles catch-up for Grades 1 to 9)		1970-07	1998-12-31
		1997-04-01 Measles (Red) second dose measles catch-up for Grades 1 – 9 (end date: 1998-06-30).			
Measles/ Rubella	MR	Measles/Rubella (second dose measles catch-up, Grades 1 to 9)		1997-01-01	1999-04-30
Measles, Mumps, Rubella	MMR	Measles/Mumps/Rubella: M-M-R® II (12 months of age routine program)	Merck Frosst	1982-10-01	

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 7 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
		Measles/Mumps/Rubella Priorix®	GlaxoSmithKline	1999 (approx.)	
		<p>1972-01-01 - Rubella (school program for Grade 6 girls).</p> <p>1982 - Measles/Mumps/Rubella routine program at 12 months of age (end date: 2010-07-31).</p> <p>1983-09-01 - Measles/Mumps/Rubella catch-up program for Grade 1 and Grade 6 (end date: 1986).</p> <p>1996-06 - Measles/Mumps/Rubella routine program second dose for 4 – 6 year olds (end date: 2010-08-31).</p> <p>1997-01-01 - Measles/Rubella second dose measles catch-up for Grades 1 – 9 (end date: 1997-12-31).</p> <p>1997-04-01 - Measles (Red) second dose measles catch-up for Grades 1 – 9 (end date: 1998-06-30).</p> <p>2007-11- Measles/Mumps/Rubella (second dose for HCW and post-secondary students). - Mass mumps campaign.</p> <p>2008-02-14 - Mumps-containing vaccine two doses for health care workers and post-secondary education students born in 1970 or later.</p> <p>2010-09-01 - Measles/Mumps/Rubella/Varicella (Priorix-Tetra®) routine program replacing MMR at 12 months of age.</p> <p>2012-08-01 - Measles/Mumps/Rubella/Varicella (Priorix-Tetra®) second dose introduced for 4- 6 years (children born August 1, 2005, or after).</p> <p>2013-09-26 - Two lifetime doses of measles-containing vaccine recommended for all adults born in 1970 or later and all health care workers regardless of birth year.</p> <p>2015-01-26 - Infants 6 months to 11 months of age and adults (born before 1970 without a documented history of measles containing vaccine, history of laboratory-confirmed measles disease or laboratory evidence of measles immunity) travelling to areas where measles is circulating in North America and all countries outside of North America should receive one dose of MMR vaccine.</p>			
Measles, Mumps, Rubella, and Varicella	MMR-Var	Measles/Mumps/Rubella/ Varicella (Priorix-Tetra®) – replacing MMR as routine program at 12 months of age	GlaxoSmithKline	2010-08-01	2022-12-01
		Measles/Mumps/Rubella/ Varicella (ProQuad™)	Merck Canada	2014-05-13	
		<p>2010-09-01 - Measles/Mumps/Rubella/Varicella (Priorix-Tetra®) routine program replacing MMR at 12 months of age.</p> <p>2012-08-01 - Measles/Mumps/Rubella/Varicella (Priorix-Tetra®) second dose introduced for 4 – 6 year olds (i.e., children born on or after August 1, 2005).</p> <p>2015-01-26 – Priorix-Tetra® for SOT candidates beginning at 9 months of age.</p>			
Meningococcal B	Men-B	Meningococcal B Multicomponent Recombinant Vaccine: Bexsero®	Novartis Vaccines and Diagnostics Inc.	2014-09-23	
	Men-B-FHbp	Meningococcal B Bivalent recombinant lipoprotein Vaccine: Trumemba®	Pfizer	2018	
		<p>2014-09-23 - Bexsero® for contacts of meningococcal B.</p> <p>2015-02-25 - Bexsero® - Indications: pre-exposure for specified high-risk individuals, outbreaks, and pre-exposure schedules depending on age.</p>			
Meningococcal Conjugate	MenC-ACYW	Meningococcal Conjugate Polysaccharide (A, C, Y,	Sanofi Pasteur	2007-02-01	

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 8 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
(Groups A, C, Y and W-135)		W-135) (Menactra®) - High-risk groups			
		Meningococcal (Groups A, C, W-135 and Y) Conjugate – (Menveo™)	Novartis	2011-02	
		Meningococcal (Groups A, C, W-135 and Y) Conjugate – (Nimenrix®)	GSK	2017-09	
		2007-02-01 - Meningococcal Conjugate Polysaccharide (A, C, Y, W-135) for high-risk groups 2 – 55 years of age. 2011-02 - Meningococcal Conjugate (Groups A, C, Y, W-135) routine Grade 9 program. 2012-01-26 - Meningococcal conjugate (groups A, C, Y, W-135) vaccine for individuals at high-risk 56 years and older. 2015-01-02 - Menveo™ to be used for high risk children 2 months to 23 months of age. 2015-02-10 – Menactra®/Menveo® updated indication for individuals with acquired complement deficiency on Solaris®			
Meningococcal Conjugate C	MenconC	Meningococcal Conjugate monovalent C (Campaign: 2 – 24 months of age)		2001-11-01	2002-03-31
		Meningococcal Conjugate - monovalent C (Universal Infant Program for infants born on or after 2001/09/01) Menjugate®	Novartis	2002-04-04	
		Meningococcal Conjugate - monovalent C: NeisVacC®	GlaxoSmithKline	2005-10	
		2001-11-01 - Meningococcal Conjugate monovalent C (Campaign: 2 – 24 months of age) (end date: 2002-03-31). 2002-04-04 - Meningococcal conjugate monovalent C vaccine infant program for infants born on or after 2001-09-01 (three dose series). 2015-01-02 - Routine meningococcal conjugate C schedule changed to 2 doses (4 and 12 months of age).			
Meningococcal Polysaccharide	MenAC MeninAC	Meningococcal Polysaccharide Bivalent A, C (Campaign - 2 to 24 years of age)		2001-02-06	2002-03-01
	MENING-P	Meningococcal polysaccharide (quadrivalent A, C, Y, W-135) - high-risk groups (Menomune®)	Connaught/ Sanofi Pasteur	1983-05-04	2012-01-18
	MENING-P (single dose) MENOTET (multi-dose)	Meningococcal Polysaccharide (quadrivalent A, C, Y, W-135) - Campaign		2000-02-15	2002-03-01
		1983-05-04 - Meningococcal polysaccharide quadrivalent A, C, Y, W-135 vaccine (Menomune®) for high-risk groups (end date:2012-01-18). 2000-02-1 - Meningococcal Polysaccharide (quadrivalent A, C, Y, W-135) – Outbreak Campaign, (end date: 2000-10-24) 2001-02-06 - Meningococcal Polysaccharide Bivalent A, C - Outbreak Campaign for 2 – 24 years of age (end date:2002-03-01).			

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 9 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
Mumps	MU	Mumps: Mumpsvox®	Merck Frosst	1982-01-01	2004-02-08
		2008-02-14 - Mumps-containing vaccine two doses for health care workers and post-secondary education students born in 1970 or later.			
Pertussis	aP	Pertussis Acellular – Acel-P	Wyeth-Ayerst	1997-07-01	2001-10
	P	Pertussis Whole Cell		1939-01-01	1997-06-30
Pneumococcal Conjugate	PNEU-C	Pneumococcal Conjugate – 7 Valent: Prevnar® (routine infant program: 4 dose series)	Wyeth	2002-09-01	2010-06-30
	PNEU-C13	Pneumococcal Conjugate - 13 Valent: Prevnar® 13 (replaced 7 valent vaccine for infant program: 3 dose series)	Wyeth	2010-07-01	
		<p>2002-09-01 - Prevnar® routine infant program using four dose series (2, 4, 6 and 18 months) (end date: 2010-06-30).</p> <p>2010-07-01 - Pneumococcal Vaccine, 13-valent Conjugate (Prevnar® 13) replaced 7 valent vaccine for infant program using three dose series (2, 4 and 12 months). High-risk children continue to receive 4 doses.</p> <ul style="list-style-type: none"> - Catch-up program for children who had completed a pneumococcal conjugate series using Prevnar® vaccine. <p>2012-02-01 - Eligibility expanded to include HIV infected individuals 6 years of age and older.</p> <p>2014-10 - Expanded indications for high-risk populations 5 – 17 years of age including: chronic cardiac disease, chronic cerebral spinal fluid (CSF) leak, chronic liver disease (including hepatitis B and C and hepatic cirrhosis due to any cause), chronic neurologic condition that may impair clearance of oral secretions, chronic pulmonary disease (excluding asthma unless treated with high-dose oral corticosteroid therapy), chronic renal disease, including nephrotic syndrome, cochlear implants (candidates and recipients), congenital immunodeficiencies diabetes mellitus (poorly controlled), immunosuppressive therapy and malignant neoplasms (leukemia, lymphoma).</p> <p>2014-10 - Expanded indications for high-risk adult populations added including: asplenia (anatomical or functional), chronic CSF leak, cochlear implants (candidates and recipients), congenital immunodeficiencies, immunosuppressive therapy, malignant neoplasms including leukemia and lymphoma, sickle cell disease and other hemoglobinopathies.</p> <p>2015-02-10 – Expanded indication to include immunosuppressive therapy regarding medication Soliris®.</p>			
Pneumococcal Polysaccharide	PNEUMO-P	Pneumococcal Polysaccharide: Pneumovax® 23 (high-risk groups) 65 years of age and older	Merck Frosst	1997-04	
				Fall 1998	
		Pneumococcal Polysaccharide: Pneumo 23®	Sanofi Pasteur	1997-04	2008-09
	<p>1997-04 - Pneumococcal Polysaccharide for high-risk groups except 65 years of age and older.</p> <p>1998-Fall - Pneumococcal Polysaccharide Vaccine for 65 years of age and older.</p> <p>2014-10 - Illicit drug use added to indications.</p> <p>2015-02-10 – Expanded indication for immunosuppressive therapy regarding medication Soliris®.</p>				

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 10 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)
Polio	IPV	Polio Inactivated (Salk) - vaccine trials: pre-licensure		1954	Unknown
		Polio Inactivated (Salk)		1956-01-01	
		Polio Inactivated (Salk) diploid cell		Unknown (vaccine introduced in Canada 1989)	2007-04-30
		Polio Inactivated (Salk) Vero Cell Origin: Imovax® Polio	Sanofi Pasteur	2007-04-09	
	OPV	Polio Oral (Sabin)	Connaught	1962-01-01	1994-07-31
		<p>1954 - Polio Inactivated (Salk) - vaccine trials: pre-licensure. 1956 - IPV introduced into the routine childhood immunization program. 1962 – Oral polio (OPV) was administered in AB. Although OPV is no longer given in AB, many countries still use this vaccine. 1994-07– IPV replaced OPV in routine immunization in combination with Diphtheria, Tetanus and Pertussis vaccine. 1995 – Polio included in a combination vaccine with tetanus, diphtheria, pertussis and Haemophilus influenza type b. 2016-04-13 - Polio Vaccine - Indications updated to be in line with CATMAT. Use of provincially funded vaccine for adults travelling to countries where polio is circulating, as per WHO Polio Emergency.</p>			
Rabies	RAB	Rabies Vaccine	Multiple manufacturers	1980-01-01	
		Rabies HDCV: Imovax® Rabies	Sanofi Pasteur	1999-08 approx.	
		Rabies PCECV: RabAvert®	Novartis	2005-06-01	
		2013-08-29 – Rabies PEP four doses of vaccine instead of five doses of vaccine for unimmunized, immune competent individuals.			
Rabies Immune Globulin	RIG	Rabies Immune Globulin	Multiple manufacturers	1983-09-16	
		Rabies Immune Globulin: Imogam® Rabies	Sanofi Pasteur	2004 -2005	
		Rabies Immune Globulin: Hyperrab® S/D	Talecris Therapeutics/ Grifols Therapeutics	2007-07	
Rotavirus	Rot	Rotavirus vaccine: Rotarix®	GSK	2015-06-01 2021-05-01	2018-06
	Rot-5	Rotavirus vaccine: RotaTeq®	Merck Canada Inc.	2018-05-01	2022-07-29
		2015-06 - Rotarix® (2 dose series) routinely offered at 2 and 4 months of age.			
Rubella	RUB	Rubella	Connaught	1971-01-01	1998-10-01
		1972-01-01 - Rubella (school program for Grade 6 females) (end date: 1982-01-01).			
Smallpox	Sma	Smallpox (vaccinia) – universal		1870-01-01	1980-04-10
		Smallpox (vaccinia) - select groups		2005-01-01	
		1870-01-01 - Smallpox (vaccinia) – universal. 2005-01 - Smallpox (vaccinia) for select laboratory workers.			

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 11 of 14



Biological Product	Vaccine Code	Biological Name/ Description/ Trade Name	Manufacturer	Start Date (Y-M-D)	End Date (Y-M-D)	
Smallpox Antiviral	Not applicable	TPOXX® Tecovirimat Capsules – select groups	SIGA Technologies Inc.	2022-06-07		
Smallpox and Monkeypox Vaccine	SMAMONV	Imvamune® (orthopox virus) - select groups	Bavarian Nordic A/S	2022-06-07		
Snakebite Antivenom	SNAKE	Snakebite Antivenom		1980-01-01	2002-03-20	
Tetanus Toxoid	TT	Tetanus Toxoid		1947-01-01	2000-12-31	
Tetanus/ Diphtheria	Td	Tetanus/Diphtheria Toxoids (adult)	Sanofi Pasteur	1980-07-09	2022-06-30	
		1980-07-09 – Introduced into program. 2004-09-01 – dTap replaced Td as routine grade 9 booster.				
Tetanus/ Diphtheria/Polio	TdP or Td-IPV	Tetanus/Diphtheria/IPV (adult)	Sanofi Pasteur Limited	2015-02-11		
		2016-04-13 - Td Polio - Indications updated to be in line with CATMAT. Use of provincially funded vaccine for adults traveling to countries where polio is circulating, as per WHO Polio Emergency.				
Tetanus Polio	TP	Tetanus Polio		1959-01-01	1994-08-01	
Tetanus Immune Globulin	TIG	Tetanus Immune Globulin (Human)	Multiple manufacturers	unknown	2006-06	
		Tetanus Immune Globulin (Human): Hypertet® S/D	Talecris Therapeutics/ Grifols Therapeutics	2006-07		
Tuberculin	PPD	Tuberculin Purified Protein Derivative 5TU (Mantoux – TB Test)	Connaught/ Sanofi Pasteur	1960-01-05		
Typhoid	TYVI	Typhoid injectable: Typherix®	GlaxoSmithKline	2004-01-19		
		Typhoid injectable: Typhim Vi®	Sanofi Pasteur S/A	2013-09-04		
Varicella	VZ	Varicella Zoster: Varivax® II and III (one year of age – phased in approach)	Merck Frosst	2001-07-01		
		Varicella Zoster: Varilrix®	GlaxoSmithKline	unknown		
		2001-03 - Varicella vaccine for non-immune special groups (household contacts of immunocompromised individuals, HCWs known to be susceptible, and women identified through routine pre-natal care). 2001-04-01 - For susceptible students in Grade 5 (phased-in approach). 2001-07-01 - Routine program for children 12 months of age born January 1, 2000, or after (phased-in approach). 2002 Spring - Catch-up program offered during the preschool immunization visit. 2003-04 - Varicella vaccine for all susceptible individuals. 2012-08 - All children born on or after August 1, 2005, eligible to receive 2 doses of varicella vaccine.				
Varicella Zoster Immune Globulin	VZIG	Varicella Immune Globulin	Multiple manufacturers – accessed through Canadian Blood Services	1985-01-01		

Alberta Immunization Program History

Alberta Immunization Policy

© 2024 Government of Alberta | Published May 2024 | Page 12 of 14



Not all vaccine manufacturers are known, or multiple manufacturers have supplied the biological product over the years since first introduced.

For additional information, please contact the manufacturer of the product and/or Health Canada.

References

- ¹ Alberta Health. (2018, September). *Immunization Data Submission and Response Guidelines, Version 6.1*. <https://open.alberta.ca/publications/immunization-data-submission-and-response-guidelines>
- ² Alberta Health and Wellness, Disease Control and Prevention. (2004, May). *Alberta's Meningococcal Immunization Program: A full report*. www.health.alberta.ca/documents/Meningococcal-Campaign-2001.pdf
- ³ AHS (former Calgary Health Region), Communicable Disease Control. (2005, November). *Dates when new programs, vaccines, etc. adopted by Calgary Health Region*.
- ⁴ AHS (former Capital Health Region), Public Health Division, Communicable Disease Control. (2002, December). Biologicals introduced in Alberta. In *Communicable Disease Control Manual* (Appendix 4).
- ⁵ Waters, John. (1996). *Biologicals introduced in Alberta*. Unpublished personal file.